ERBB2 and gastric cancer: In 2020, the DESTINY-Gastric01 trial showed that trastuzumab deruxtecan (T-DXd), an antibody–drug conjugate consisting of a humanized monoclonal anti-HER2 antibody bound to a cytotoxic topoisomerase I inhibitor (drug payload) by means of a cleavable tetra peptide-based linker, significantly improved the overall survival of HER2-positive advanced GC [9].